U.S. Defense Bill Targets Tech Investment and Biotech Deals with China

The U.S. Congress is set to vote on a major defense bill containing new restrictions on American investment in Chinese technology and on federal contracts with Chinese biotechnology firms. These measures, which failed to pass in previous legislation, are now part of a compromise agreement. Lawmakers released the annual National Defense Authorization Act (NDAA) on Sunday following months of negotiations. Votes in both the House and Senate could occur this week. The proposed rules would limit U.S. financial investments into China's sensitive high-tech sectors. A separate provision would block U.S. government agencies from signing contracts with certain Chinese biotech companies. If passed, the NDAA would become a key law shaping economic and security policy toward China. The bill must clear both chambers of Congress before being sent to the President.